Login to Your Account

Cephalon Buys Back $50M JV Through Convertible Placement

By Randall Osborne

Tuesday, April 2, 2002
Paying $55 million, Cephalon Inc. bought back the interest of two unaffiliated investors in a joint venture formed in December to put as much as $50 million into U.S. commercial efforts on behalf of Provigil for sleep disorders and Gabitril for epilepsy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription